The gene-editing technology developer received further support from SoftBank Vision Fund 2 to advance its genomics drug discovery platform.

US-based genomic drug developer Tessera Therapeutics secured over $300m in series C funding from investors including internet and telecommunications group SoftBank’s Vision Fund 2 yesterday. Hanwha Impact Partners, a branch of diversified conglomerate Hanwha, also took part in the round, as did life sciences-focused venture builder Flagship Pioneering, Alaska Permanent Fund Corporation and a subsidiary…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.